French Authorities Approve Reimbursement of Orkambi for CF Patients 2 Years and Older
Nov 22, 2019 07:00 am | Iqra Mumal MSc
The Comité Économique des Produits de Santé (CEPS) in France has approved national reimbursement of Vertex Pharmaceuticals’ Orkambi (lumacaftor/ivacaftor) for patients with cystic fibrosis (CF) who are 2 years of age or older, with two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (the gene defective in CF). Once the agreement has […]
The post French Authorities Approve Reimbursement of Orkambi for CF Patients 2 Years and Older appeared first on Cystic Fibrosis News Today. |
|
NIH Grants $2.7M for Research on Anaerobic Bacteria’s Role in CF Flare-ups
Nov 21, 2019 07:00 am | Iqra Mumal MSc
The National Institutes of Health (NIH) has granted $2.7 million to Michigan State University (MSU) scientist Robert Quinn to investigate, in collaboration with Spectrum Health, the role of anaerobic bacteria in the development of flare-ups among patients with cystic fibrosis (CF). Anaerobic bacteria are a type of bacteria that live without oxygen, and are frequently […]
The post NIH Grants $2.7M for Research on Anaerobic Bacteria’s Role in CF Flare-ups appeared first on Cystic Fibrosis News Today. |
|
Attending This Year’s North American Cystic Fibrosis Conference Gave Me Hope
Nov 20, 2019 03:00 pm | Ella Balasa
Two weeks ago, I watched a livestream of the North American Cystic Fibrosis Conference (NACFC) as I popped Trikafta (elexacaftor/tezacaftor/ivacaftor) tablets out of their blister pack. Francis Collins, one of the researchers who discovered the cystic fibrosis transmembrane conductance regulator (CFTR) gene, was singing to an audience of thousands. I teared up when he sang, “Dare […]
The post Attending This Year’s North American Cystic Fibrosis Conference Gave Me Hope appeared first on Cystic Fibrosis News Today. |
|
|
No hay comentarios:
Publicar un comentario